Digital regulation continues to be at the forefront of regulator concerns, as authorities focus on technology companies through traditional antitrust tools and new digital markets regimes. Further legislation and guidance is...more
In 2024, regulators across the globe increasingly acknowledged the need for a nuanced enforcement approach to balancing support for sustainability initiatives against traditional antitrust enforcement and countering the risk...more
3/21/2025
/ Antitrust Provisions ,
Competition ,
Environmental Policies ,
Environmental Social & Governance (ESG) ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Greenwashing ,
Popular ,
Sustainability ,
UK
Overall, global fines for cartel activity in 2024 (USD602.5 million) were the lowest recorded for several years, and significantly lower than the 2023 total (USD1.9billion). Unlike in previous years, 2024 saw relatively few...more
Continuing the trend from 2023, 2024 saw an increase by regulators across the globe in activity in relation to labor markets, with new investigations being opened in all sectors of the economy, enforcement action, and updates...more
This newsletter is a summary of the antitrust developments we think are most interesting to your business. Thomas Masterman, partner based in London, is our editor this month. He has selected:
Out now: our latest global...more
4/2/2024
/ Acquisitions ,
Antitrust Division ,
Antitrust Provisions ,
Capital Markets ,
Cartels ,
Competition ,
Department of Justice (DOJ) ,
Enforcement Actions ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Global Market ,
Investment ,
Mergers ,
Private Equity ,
Private Equity Firms ,
Regulatory Agenda ,
Regulatory Reform ,
UK ,
UK Competition and Markets Authority (CMA)
Public input -
As we wrote a couple of months ago, antitrust authorities of the US, Canada, UK, and EU formed, in March, an international working group: the Multilateral Pharmaceutical Merger Task Force (the Task Force)....more
Working group’s goal is “concrete and actionable” updates to pharmaceutical merger analysis....more